Inflammation as an underlying driver of aging
PrimaryAISA Therapeutics' central causal theory is that chronic inflammation underlies aging, so non-toxic anti-inflammatory interventions should slow or reduce biological processes associated with senescence and age-related decline. Under this model, products that lower inflammatory burden are expected to produce anti-senescence effects and improve healthspan-relevant outcomes. Testable predictions include reduced inflammatory biomarkers after intervention, reduced markers or consequences of cellular senescence, and improved age-associated functional or quality-of-life outcomes in older adults receiving AISA anti-inflammatory actives.
Popperian evaluation
Inflammaging is a credible, well-established concept in geroscience, first formalized by Franceschi around 2000. Chronic low-grade inflammation does correlate with age-related disease across large epidemiological datasets. The weak point is causal direction: inflammation may be downstream of other aging processes (mitochondrial dysfunction, senescent cell accumulation, epigenetic drift) rather than a primary driver. The supporting publications here are thin for the weight of the claim. One is a hypothesis paper ('Salutogenesis and beyond') that discusses paradoxes in preventive medicine without providing direct mechanistic evidence for inflammation-causes-aging. The other is a diet trial (RISTOMED) that measured inflammation as an outcome, not as a validated causal intermediate. The assumption that short-term biomarker changes in a two-month dietary intervention reflect long-term effects on aging biology is explicitly flagged as low-confidence in the reasoning nodes, and rightly so.
Supporting evidence: Inflammaging is a mainstream geroscience concept with broad epidemiological support linking CRP, IL-6, and TNF-alpha elevations to age-related multimorbidity.; The RISTOMED trial reported that the dietary intervention reduced inflammation in older adults (125 subjects, 65-80 years), consistent with the premise that inflammatory burden is modifiable.
Counter evidence: The reasoning nodes themselves assign only 'low' confidence to the assumption that short-term biomarker changes indicate meaningful effects on aging biology.; Neither supporting publication provides mechanistic evidence that inflammation is causally upstream of senescence rather than a parallel or downstream consequence.; The 'Salutogenesis and beyond' paper is a hypothesis/opinion piece, not primary research establishing the causal chain.
The theory's own best evidence actively undermines its explanatory logic. The RISTOMED trial found that depressive symptom improvement was independent of baseline inflammation status. That is a direct problem: if the claimed mechanism is 'reduce inflammation → improve healthspan outcomes,' and the one trial you cite shows improvement that does not track with inflammation, the theory fails to explain its own positive result. Physical health QoL and anxiety scores did not change at all. Mental health QoL improved in only two of four arms (healthy diet alone and healthy diet plus d-Limonene), but the trial had no true control group, so participation effects and regression to the mean are uncontrolled confounders. The theory cannot distinguish 'anti-inflammatory nutraceutical slows aging' from 'eating better for two months modestly improves mood in elderly volunteers,' which is a far more parsimonious explanation. No senescence markers were measured in any cited study, so the central causal chain (inflammation → senescence → decline) has zero direct observational support here.
Supporting evidence: CES-D depression scores decreased across all four RISTOMED arms, including the d-Limonene arm (−42.8%, p = 0.004).; Mental health-related quality of life improved in the healthy diet arm and the healthy diet plus d-Limonene arm.
Counter evidence: The RISTOMED trial explicitly reported that depressive symptom improvement was independent of baseline inflammation, severing the proposed causal link between inflammation reduction and quality-of-life gains.; No change was observed in anxiety or physical health-related quality of life, which the theory would predict should also improve if inflammatory burden were reduced.; No senescence biomarkers (p16, SA-β-gal, SASP factors) were measured in any cited study, leaving the inflammation → senescence link entirely untested.; The trial was open-label with no true control group, so placebo, expectancy, and participation effects are uncontrolled alternative explanations.
The theory does generate testable predictions, which is genuinely to its credit: reduced inflammatory biomarkers, reduced cellular senescence markers, improved functional outcomes in older adults. These are measurable with existing assays. The problem is practical, not logical. The predictions are broad enough to permit selective endpoint reporting: 'improved age-associated functional or quality-of-life outcomes' covers dozens of instruments, and a motivated investigator can find one that moves. The RISTOMED trial illustrates the pattern: depression scores improved, physical QoL did not, anxiety did not, and the improvement was unrelated to inflammation. A strict falsificationist would call this a partial refutation of the causal chain, but the theory's framing is loose enough to absorb the hit. A stronger falsifiability setup would pre-register specific biomarker thresholds and a defined causal mediation analysis (does CRP reduction mediate senescence marker reduction, which mediates functional improvement?). No such design exists in the cited evidence.
Supporting evidence: Three concrete prediction nodes are specified: inflammatory biomarker reduction, senescence marker reduction, and functional/QoL improvement. All are measurable with standard assays.; The RISTOMED trial did measure inflammatory parameters and multiple QoL instruments, showing the predictions are operationalizable.
Counter evidence: The breadth of 'age-associated functional or quality-of-life outcomes' allows post-hoc endpoint selection, weakening practical falsifiability.; No pre-registered mediation analysis links the three predictions into a testable causal chain (inflammation reduction → senescence reduction → functional improvement).; The open-label, no-control design of RISTOMED makes it difficult to distinguish genuine falsification from noise, limiting the practical bite of any negative result.
Reasoning tree
Public endorsements
D'Alessio does not merely mention this theory; she has organised her entire professional output around it. The company she founded in 2005 is named AISA Therapeutics, an acronym that stands for Anti-Inflammatory Senescence Actives, and its stated vision is 'Inflammation is at the basis of aging.' The RISTOMED trial, which she remained at university to complete, produced what the company calls 'first human evidence of the anti-inflammatory efficacy of d-Limonene.' She has chaired the 'inflammaging' session at SIME for at least three consecutive years. Her own website lists 'Senescence & inflammaging' as a core science pillar alongside stress and gut-brain-skin axis content. Every public surface she controls — conference roles, company branding, product rationale — reflects the same causal claim: chronic inflammation drives senescence and aging, and non-toxic anti-inflammatory actives can slow that process. This is not endorsement by association; it is the foundational premise she has publicly defended across a 20-year research-to-product arc.
Evidence publication IDs: fda5c7c3-28ff-4d11-bbc4-6453fe6648ef, 342397eb-d3ab-4b90-8b66-bd8d09457945